Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis
Identifieur interne : 001768 ( Ncbi/Merge ); précédent : 001767; suivant : 001769Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis
Auteurs : Kristian Thorlund [Canada, États-Unis] ; Ping Wu [Canada] ; Eric Druyts [Canada] ; Shawn Eapen [Canada] ; Edward J. Mills [États-Unis, Canada]Source :
- Neuropsychiatric Disease and Treatment [ 1176-6328 ] ; 2014.
Abstract
To compare the efficacy of the three nonergot dopamine-receptor agonists (DAs) pramipexole, ropinirole, and rotigotine for the treatment of early and advanced Parkinson’s disease (PD).
Bayesian network meta-analyses were performed separately for early and advanced PD, and at time points 11–16 and 24–28 weeks. Outcomes for early PD included improvement on the Unified Parkinson’s Disease Rating Scale (UPDRS) activities in daily life (UPDRS-II), motor function (UPDRS-III), and their subtotal (UPDRS-II + III). Outcomes for advanced PD also included daily “off time” (hours), but not UPDRS-II + III.
Totals of 23 and 24 trials informed early and advanced PD analyses. For early PD UPDRS-II at 11–16 weeks, pramipexole and rotigotine were statistically significantly superior to placebo, but ropinirole was not. For UPDRS-III and UPDRS-II + III, all DAs were statistically significantly better than placebo and exhibited similar improvements. At 24–28 weeks, results were also statistically significant for all DAs versus placebo, and the magnitudes of improvements were similar for pramipexole, ropinirole and rotigotine. Advanced PD improvements on UPDRS-II, UPRDS-III, and off time were statistically significant for pramipexole, ropinirole, and rotigotine versus placebo. At 11–16 weeks, rotigotine yielded slightly smaller effects than ropinirole and pramipexole, but credible intervals on differences were wide. For off time, results were near identical. At 24–28 weeks, results were similar for all three outcomes. Ropinirole yielded a slightly higher improvement on UPDRS-III, but a slightly smaller improvement in off time.
Our analyses suggest that pramipexole, ropinirole, and rotigotine exhibit similar efficacy in the treatment of early and advanced PD.
Url:
DOI: 10.2147/NDT.S60061
PubMed: 24855362
PubMed Central: 4019622
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000A54
- to stream Pmc, to step Curation: 000A54
- to stream Pmc, to step Checkpoint: 000437
Links to Exploration step
PMC:4019622Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis</title><author><name sortKey="Thorlund, Kristian" sort="Thorlund, Kristian" uniqKey="Thorlund K" first="Kristian" last="Thorlund">Kristian Thorlund</name><affiliation wicri:level="4"><nlm:aff id="af1-ndt-10-767">Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON</wicri:regionArea><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="af2-ndt-10-767">Stanford Prevention Research Center, Stanford University, Stanford, CA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Stanford Prevention Research Center, Stanford University, Stanford, CA</wicri:regionArea><wicri:noRegion>CA</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="af4-ndt-10-767">Redwood Outcomes, Vancouver, BC, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Redwood Outcomes, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Wu, Ping" sort="Wu, Ping" uniqKey="Wu P" first="Ping" last="Wu">Ping Wu</name><affiliation wicri:level="1"><nlm:aff id="af3-ndt-10-767">Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Health Sciences, University of Ottawa, Ottawa, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="af4-ndt-10-767">Redwood Outcomes, Vancouver, BC, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Redwood Outcomes, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Druyts, Eric" sort="Druyts, Eric" uniqKey="Druyts E" first="Eric" last="Druyts">Eric Druyts</name><affiliation wicri:level="1"><nlm:aff id="af3-ndt-10-767">Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Health Sciences, University of Ottawa, Ottawa, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="af4-ndt-10-767">Redwood Outcomes, Vancouver, BC, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Redwood Outcomes, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Eapen, Shawn" sort="Eapen, Shawn" uniqKey="Eapen S" first="Shawn" last="Eapen">Shawn Eapen</name><affiliation wicri:level="1"><nlm:aff id="af3-ndt-10-767">Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Health Sciences, University of Ottawa, Ottawa, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="af4-ndt-10-767">Redwood Outcomes, Vancouver, BC, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Redwood Outcomes, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Mills, Edward J" sort="Mills, Edward J" uniqKey="Mills E" first="Edward J" last="Mills">Edward J. Mills</name><affiliation wicri:level="1"><nlm:aff id="af2-ndt-10-767">Stanford Prevention Research Center, Stanford University, Stanford, CA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Stanford Prevention Research Center, Stanford University, Stanford, CA</wicri:regionArea><wicri:noRegion>CA</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="af3-ndt-10-767">Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Health Sciences, University of Ottawa, Ottawa, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="af4-ndt-10-767">Redwood Outcomes, Vancouver, BC, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Redwood Outcomes, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24855362</idno><idno type="pmc">4019622</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019622</idno><idno type="RBID">PMC:4019622</idno><idno type="doi">10.2147/NDT.S60061</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">000A54</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000A54</idno><idno type="wicri:Area/Pmc/Curation">000A54</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000A54</idno><idno type="wicri:Area/Pmc/Checkpoint">000437</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000437</idno><idno type="wicri:Area/Ncbi/Merge">001768</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis</title><author><name sortKey="Thorlund, Kristian" sort="Thorlund, Kristian" uniqKey="Thorlund K" first="Kristian" last="Thorlund">Kristian Thorlund</name><affiliation wicri:level="4"><nlm:aff id="af1-ndt-10-767">Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON</wicri:regionArea><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="af2-ndt-10-767">Stanford Prevention Research Center, Stanford University, Stanford, CA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Stanford Prevention Research Center, Stanford University, Stanford, CA</wicri:regionArea><wicri:noRegion>CA</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="af4-ndt-10-767">Redwood Outcomes, Vancouver, BC, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Redwood Outcomes, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Wu, Ping" sort="Wu, Ping" uniqKey="Wu P" first="Ping" last="Wu">Ping Wu</name><affiliation wicri:level="1"><nlm:aff id="af3-ndt-10-767">Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Health Sciences, University of Ottawa, Ottawa, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="af4-ndt-10-767">Redwood Outcomes, Vancouver, BC, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Redwood Outcomes, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Druyts, Eric" sort="Druyts, Eric" uniqKey="Druyts E" first="Eric" last="Druyts">Eric Druyts</name><affiliation wicri:level="1"><nlm:aff id="af3-ndt-10-767">Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Health Sciences, University of Ottawa, Ottawa, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="af4-ndt-10-767">Redwood Outcomes, Vancouver, BC, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Redwood Outcomes, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Eapen, Shawn" sort="Eapen, Shawn" uniqKey="Eapen S" first="Shawn" last="Eapen">Shawn Eapen</name><affiliation wicri:level="1"><nlm:aff id="af3-ndt-10-767">Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Health Sciences, University of Ottawa, Ottawa, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="af4-ndt-10-767">Redwood Outcomes, Vancouver, BC, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Redwood Outcomes, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Mills, Edward J" sort="Mills, Edward J" uniqKey="Mills E" first="Edward J" last="Mills">Edward J. Mills</name><affiliation wicri:level="1"><nlm:aff id="af2-ndt-10-767">Stanford Prevention Research Center, Stanford University, Stanford, CA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Stanford Prevention Research Center, Stanford University, Stanford, CA</wicri:regionArea><wicri:noRegion>CA</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="af3-ndt-10-767">Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Health Sciences, University of Ottawa, Ottawa, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="af4-ndt-10-767">Redwood Outcomes, Vancouver, BC, Canada</nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Redwood Outcomes, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author></analytic><series><title level="j">Neuropsychiatric Disease and Treatment</title><idno type="ISSN">1176-6328</idno><idno type="eISSN">1178-2021</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Objective</title><p>To compare the efficacy of the three nonergot dopamine-receptor agonists (DAs) pramipexole, ropinirole, and rotigotine for the treatment of early and advanced Parkinson’s disease (PD).</p></sec><sec><title>Materials and methods</title><p>Bayesian network meta-analyses were performed separately for early and advanced PD, and at time points 11–16 and 24–28 weeks. Outcomes for early PD included improvement on the Unified Parkinson’s Disease Rating Scale (UPDRS) activities in daily life (UPDRS-II), motor function (UPDRS-III), and their subtotal (UPDRS-II + III). Outcomes for advanced PD also included daily “off time” (hours), but not UPDRS-II + III.</p></sec><sec><title>Results</title><p>Totals of 23 and 24 trials informed early and advanced PD analyses. For early PD UPDRS-II at 11–16 weeks, pramipexole and rotigotine were statistically significantly superior to placebo, but ropinirole was not. For UPDRS-III and UPDRS-II + III, all DAs were statistically significantly better than placebo and exhibited similar improvements. At 24–28 weeks, results were also statistically significant for all DAs versus placebo, and the magnitudes of improvements were similar for pramipexole, ropinirole and rotigotine. Advanced PD improvements on UPDRS-II, UPRDS-III, and off time were statistically significant for pramipexole, ropinirole, and rotigotine versus placebo. At 11–16 weeks, rotigotine yielded slightly smaller effects than ropinirole and pramipexole, but credible intervals on differences were wide. For off time, results were near identical. At 24–28 weeks, results were similar for all three outcomes. Ropinirole yielded a slightly higher improvement on UPDRS-III, but a slightly smaller improvement in off time.</p></sec><sec><title>Conclusion</title><p>Our analyses suggest that pramipexole, ropinirole, and rotigotine exhibit similar efficacy in the treatment of early and advanced PD.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Sweet, Rd" uniqKey="Sweet R">RD Sweet</name></author><author><name sortKey="Mcdowell, Fh" uniqKey="Mcdowell F">FH McDowell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lesser, Rp" uniqKey="Lesser R">RP Lesser</name></author><author><name sortKey="Fahn, S" uniqKey="Fahn S">S Fahn</name></author><author><name sortKey="Snider, Sr" uniqKey="Snider S">SR Snider</name></author><author><name sortKey="Cote, Lj" uniqKey="Cote L">LJ Cote</name></author><author><name sortKey="Isgreen, Wp" uniqKey="Isgreen W">WP Isgreen</name></author><author><name sortKey="Barrett, Re" uniqKey="Barrett R">RE Barrett</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Brooks, Dj" uniqKey="Brooks D">DJ Brooks</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Steiger, M" uniqKey="Steiger M">M Steiger</name></author><author><name sortKey="Jost, W" uniqKey="Jost W">W Jost</name></author><author><name sortKey="Grandas, F" uniqKey="Grandas F">F Grandas</name></author><author><name sortKey="Van Camp, G" uniqKey="Van Camp G">G Van Camp</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kulisevsky, J" uniqKey="Kulisevsky J">J Kulisevsky</name></author><author><name sortKey="Pagonabarraga, J" uniqKey="Pagonabarraga J">J Pagonabarraga</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leentjens, Af" uniqKey="Leentjens A">AF Leentjens</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lu, G" uniqKey="Lu G">G Lu</name></author><author><name sortKey="Ades, Ae" uniqKey="Ades A">AE Ades</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dias, S" uniqKey="Dias S">S Dias</name></author><author><name sortKey="Welton, N" uniqKey="Welton N">N Welton</name></author><author><name sortKey="Sutton, A" uniqKey="Sutton A">A Sutton</name></author><author><name sortKey="Ades, A" uniqKey="Ades A">A Ades</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mills, Ej" uniqKey="Mills E">EJ Mills</name></author><author><name sortKey="Ioannidis, Jp" uniqKey="Ioannidis J">JP Ioannidis</name></author><author><name sortKey="Thorlund, K" uniqKey="Thorlund K">K Thorlund</name></author><author><name sortKey="Schunemann, Hj" uniqKey="Schunemann H">HJ Schunemann</name></author><author><name sortKey="Puhan, Ma" uniqKey="Puhan M">MA Puhan</name></author><author><name sortKey="Guyatt, Gh" uniqKey="Guyatt G">GH Guyatt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lunn, D" uniqKey="Lunn D">D Lunn</name></author><author><name sortKey="Spiegelhalter, D" uniqKey="Spiegelhalter D">D Spiegelhalter</name></author><author><name sortKey="Thomas, A" uniqKey="Thomas A">A Thomas</name></author><author><name sortKey="Best, N" uniqKey="Best N">N Best</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Giladi, N" uniqKey="Giladi N">N Giladi</name></author><author><name sortKey="Boroojerdi, B" uniqKey="Boroojerdi B">B Boroojerdi</name></author><author><name sortKey="Korczyn, Ad" uniqKey="Korczyn A">AD Korczyn</name></author><author><name sortKey="Burn, Dj" uniqKey="Burn D">DJ Burn</name></author><author><name sortKey="Clarke, Ce" uniqKey="Clarke C">CE Clarke</name></author><author><name sortKey="Schapira, Ah" uniqKey="Schapira A">AH Schapira</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rascol, O" uniqKey="Rascol O">O Rascol</name></author><author><name sortKey="Brooks, Dj" uniqKey="Brooks D">DJ Brooks</name></author><author><name sortKey="Korczyn, Ad" uniqKey="Korczyn A">AD Korczyn</name></author><author><name sortKey="De Deyn, Pp" uniqKey="De Deyn P">PP De Deyn</name></author><author><name sortKey="Clarke, Ce" uniqKey="Clarke C">CE Clarke</name></author><author><name sortKey="Lang, Ae" uniqKey="Lang A">AE Lang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Singer, C" uniqKey="Singer C">C Singer</name></author><author><name sortKey="Lamb, J" uniqKey="Lamb J">J Lamb</name></author><author><name sortKey="Ellis, A" uniqKey="Ellis A">A Ellis</name></author><author><name sortKey="Layton, G" uniqKey="Layton G">G Layton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Watts, Rl" uniqKey="Watts R">RL Watts</name></author><author><name sortKey="Lyons, Ke" uniqKey="Lyons K">KE Lyons</name></author><author><name sortKey="Pahwa, R" uniqKey="Pahwa R">R Pahwa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mizuno, Y" uniqKey="Mizuno Y">Y Mizuno</name></author><author><name sortKey="Kondo, T" uniqKey="Kondo T">T Kondo</name></author><author><name sortKey="Hasegawa, K" uniqKey="Hasegawa K">K Hasegawa</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Shannon, Km" uniqKey="Shannon K">KM Shannon</name></author><author><name sortKey="Bennett, Jp" uniqKey="Bennett J">JP Bennett</name></author><author><name sortKey="Friedman, Jh" uniqKey="Friedman J">JH Friedman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kulisevsky, J" uniqKey="Kulisevsky J">J Kulisevsky</name></author><author><name sortKey="L Pez Villegas, D" uniqKey="L Pez Villegas D">D López-Villegas</name></author><author><name sortKey="Garcia Sanchez, C" uniqKey="Garcia Sanchez C">C García-Sánchez</name></author><author><name sortKey="Barbanoj, M" uniqKey="Barbanoj M">M Barbanoj</name></author><author><name sortKey="Gironell, A" uniqKey="Gironell A">A Gironell</name></author><author><name sortKey="Pascual Sedano, B" uniqKey="Pascual Sedano B">B Pascual-Sedano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barone, P" uniqKey="Barone P">P Barone</name></author><author><name sortKey="Bravi, D" uniqKey="Bravi D">D Bravi</name></author><author><name sortKey="Bermejo Pareja, F" uniqKey="Bermejo Pareja F">F Bermejo-Pareja</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barone, P" uniqKey="Barone P">P Barone</name></author><author><name sortKey="Poewe, W" uniqKey="Poewe W">W Poewe</name></author><author><name sortKey="Albrecht, S" uniqKey="Albrecht S">S Albrecht</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wong, Ks" uniqKey="Wong K">KS Wong</name></author><author><name sortKey="Lu, Cs" uniqKey="Lu C">CS Lu</name></author><author><name sortKey="Shan, De" uniqKey="Shan D">DE Shan</name></author><author><name sortKey="Yang, Cc" uniqKey="Yang C">CC Yang</name></author><author><name sortKey="Tsoi, Th" uniqKey="Tsoi T">TH Tsoi</name></author><author><name sortKey="Mok, V" uniqKey="Mok V">V Mok</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kieburtz, K" uniqKey="Kieburtz K">K Kieburtz</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Thomas, A" uniqKey="Thomas A">A Thomas</name></author><author><name sortKey="Bonanni, L" uniqKey="Bonanni L">L Bonanni</name></author><author><name sortKey="Di Iorio, A" uniqKey="Di Iorio A">A Di Iorio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Poewe, W" uniqKey="Poewe W">W Poewe</name></author><author><name sortKey="Rascol, O" uniqKey="Rascol O">O Rascol</name></author><author><name sortKey="Barone, P" uniqKey="Barone P">P Barone</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sampaio, C" uniqKey="Sampaio C">C Sampaio</name></author><author><name sortKey="Bronzova, J" uniqKey="Bronzova J">J Bronzova</name></author><author><name sortKey="Hauser, Ra" uniqKey="Hauser R">RA Hauser</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jankovic, J" uniqKey="Jankovic J">J Jankovic</name></author><author><name sortKey="Watts, Rl" uniqKey="Watts R">RL Watts</name></author><author><name sortKey="Martin, W" uniqKey="Martin W">W Martin</name></author><author><name sortKey="Boroojerdi, B" uniqKey="Boroojerdi B">B Boroojerdi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hauser, Ra" uniqKey="Hauser R">RA Hauser</name></author><author><name sortKey="Schapira, Ah" uniqKey="Schapira A">AH Schapira</name></author><author><name sortKey="Rascol, O" uniqKey="Rascol O">O Rascol</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brooks, Dj" uniqKey="Brooks D">DJ Brooks</name></author><author><name sortKey="Abbott, Rj" uniqKey="Abbott R">RJ Abbott</name></author><author><name sortKey="Lees, Aj" uniqKey="Lees A">AJ Lees</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Whone, Al" uniqKey="Whone A">AL Whone</name></author><author><name sortKey="Watts, Rl" uniqKey="Watts R">RL Watts</name></author><author><name sortKey="Stoessl, Aj" uniqKey="Stoessl A">AJ Stoessl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oertel, Wh" uniqKey="Oertel W">WH Oertel</name></author><author><name sortKey="Wolters, E" uniqKey="Wolters E">E Wolters</name></author><author><name sortKey="Sampaio, C" uniqKey="Sampaio C">C Sampaio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Navan, P" uniqKey="Navan P">P Navan</name></author><author><name sortKey="Findley, Lj" uniqKey="Findley L">LJ Findley</name></author><author><name sortKey="Jeffs, Ja" uniqKey="Jeffs J">JA Jeffs</name></author><author><name sortKey="Pearce, Rk" uniqKey="Pearce R">RK Pearce</name></author><author><name sortKey="Bain, Pg" uniqKey="Bain P">PG Bain</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Korczyn, Ad" uniqKey="Korczyn A">AD Korczyn</name></author><author><name sortKey="Brunt, Er" uniqKey="Brunt E">ER Brunt</name></author><author><name sortKey="Larsen, Jp" uniqKey="Larsen J">JP Larsen</name></author><author><name sortKey="Nagy, Z" uniqKey="Nagy Z">Z Nagy</name></author><author><name sortKey="Poewe, Wh" uniqKey="Poewe W">WH Poewe</name></author><author><name sortKey="Ruggieri, S" uniqKey="Ruggieri S">S Ruggieri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Adler, Ch" uniqKey="Adler C">CH Adler</name></author><author><name sortKey="Sethi, Kd" uniqKey="Sethi K">KD Sethi</name></author><author><name sortKey="Hauser, Ra" uniqKey="Hauser R">RA Hauser</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Poewe, Wh" uniqKey="Poewe W">WH Poewe</name></author><author><name sortKey="Rascol, O" uniqKey="Rascol O">O Rascol</name></author><author><name sortKey="Quinn, N" uniqKey="Quinn N">N Quinn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koller, W" uniqKey="Koller W">W Koller</name></author><author><name sortKey="Lees, A" uniqKey="Lees A">A Lees</name></author><author><name sortKey="Doder, M" uniqKey="Doder M">M Doder</name></author><author><name sortKey="Hely, M" uniqKey="Hely M">M Hely</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lieberman, A" uniqKey="Lieberman A">A Lieberman</name></author><author><name sortKey="Olanow, Cw" uniqKey="Olanow C">CW Olanow</name></author><author><name sortKey="Sethi, K" uniqKey="Sethi K">K Sethi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pinter, Mm" uniqKey="Pinter M">MM Pinter</name></author><author><name sortKey="Pogarell, O" uniqKey="Pogarell O">O Pogarell</name></author><author><name sortKey="Oertel, Wh" uniqKey="Oertel W">WH Oertel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schapira, Ah" uniqKey="Schapira A">AH Schapira</name></author><author><name sortKey="Barone, P" uniqKey="Barone P">P Barone</name></author><author><name sortKey="Hauser, Ra" uniqKey="Hauser R">RA Hauser</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mizuno, Y" uniqKey="Mizuno Y">Y Mizuno</name></author><author><name sortKey="Yanagisawa, N" uniqKey="Yanagisawa N">N Yanagisawa</name></author><author><name sortKey="Kuno, S" uniqKey="Kuno S">S Kuno</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lieberman, A" uniqKey="Lieberman A">A Lieberman</name></author><author><name sortKey="Ranhosky, A" uniqKey="Ranhosky A">A Ranhosky</name></author><author><name sortKey="Korts, D" uniqKey="Korts D">D Korts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hutton, Jt" uniqKey="Hutton J">JT Hutton</name></author><author><name sortKey="Koller, Wc" uniqKey="Koller W">WC Koller</name></author><author><name sortKey="Ahlskog, Je" uniqKey="Ahlskog J">JE Ahlskog</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mizuno, Y" uniqKey="Mizuno Y">Y Mizuno</name></author><author><name sortKey="Abe, T" uniqKey="Abe T">T Abe</name></author><author><name sortKey="Hasegawa, K" uniqKey="Hasegawa K">K Hasegawa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Trenkwalder, C" uniqKey="Trenkwalder C">C Trenkwalder</name></author><author><name sortKey="Kies, B" uniqKey="Kies B">B Kies</name></author><author><name sortKey="Rudzinska, M" uniqKey="Rudzinska M">M Rudzinska</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pahwa, R" uniqKey="Pahwa R">R Pahwa</name></author><author><name sortKey="Stacy, Ma" uniqKey="Stacy M">MA Stacy</name></author><author><name sortKey="Factor, Sa" uniqKey="Factor S">SA Factor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barone, P" uniqKey="Barone P">P Barone</name></author><author><name sortKey="Lamb, J" uniqKey="Lamb J">J Lamb</name></author><author><name sortKey="Ellis, A" uniqKey="Ellis A">A Ellis</name></author><author><name sortKey="Clarke, Z" uniqKey="Clarke Z">Z Clarke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guttman, M" uniqKey="Guttman M">M Guttman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moller, Jc" uniqKey="Moller J">JC Möller</name></author><author><name sortKey="Oertel, Wh" uniqKey="Oertel W">WH Oertel</name></author><author><name sortKey="Koster, J" uniqKey="Koster J">J Köster</name></author><author><name sortKey="Pezzoli, G" uniqKey="Pezzoli G">G Pezzoli</name></author><author><name sortKey="Provinciali, L" uniqKey="Provinciali L">L Provinciali</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lewitt, Pa" uniqKey="Lewitt P">PA LeWitt</name></author><author><name sortKey="Lyons, Ke" uniqKey="Lyons K">KE Lyons</name></author><author><name sortKey="Pahwa, R" uniqKey="Pahwa R">R Pahwa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Im, Jh" uniqKey="Im J">JH Im</name></author><author><name sortKey="Ha, Jh" uniqKey="Ha J">JH Ha</name></author><author><name sortKey="Cho, Is" uniqKey="Cho I">IS Cho</name></author><author><name sortKey="Lee, Mc" uniqKey="Lee M">MC Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Inzelberg, R" uniqKey="Inzelberg R">R Inzelberg</name></author><author><name sortKey="Nisipeanu, P" uniqKey="Nisipeanu P">P Nisipeanu</name></author><author><name sortKey="Rabey, Jm" uniqKey="Rabey J">JM Rabey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rektorova, I" uniqKey="Rektorova I">I Rektorová</name></author><author><name sortKey="Rektor, I" uniqKey="Rektor I">I Rektor</name></author><author><name sortKey="Bares, M" uniqKey="Bares M">M Bares</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brunt, Er" uniqKey="Brunt E">ER Brunt</name></author><author><name sortKey="Brooks, Dj" uniqKey="Brooks D">DJ Brooks</name></author><author><name sortKey="Korczyn, Ad" uniqKey="Korczyn A">AD Korczyn</name></author><author><name sortKey="Montastruc, Jl" uniqKey="Montastruc J">JL Montastruc</name></author><author><name sortKey="Stocchi, F" uniqKey="Stocchi F">F Stocchi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Steiger, Mj" uniqKey="Steiger M">MJ Steiger</name></author><author><name sortKey="El Debas, T" uniqKey="El Debas T">T El-Debas</name></author><author><name sortKey="Anderson, T" uniqKey="Anderson T">T Anderson</name></author><author><name sortKey="Findley, Lj" uniqKey="Findley L">LJ Findley</name></author><author><name sortKey="Marsden, Cd" uniqKey="Marsden C">CD Marsden</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wermuth, L" uniqKey="Wermuth L">L Wermuth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rascol, O" uniqKey="Rascol O">O Rascol</name></author><author><name sortKey="Lees, Aj" uniqKey="Lees A">AJ Lees</name></author><author><name sortKey="Senard, Jm" uniqKey="Senard J">JM Senard</name></author><author><name sortKey="Pirtosek, Z" uniqKey="Pirtosek Z">Z Pirtosek</name></author><author><name sortKey="Montastruc, Jl" uniqKey="Montastruc J">JL Montastruc</name></author><author><name sortKey="Fuell, D" uniqKey="Fuell D">D Fuell</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Neuropsychiatr Dis Treat</journal-id><journal-id journal-id-type="iso-abbrev">Neuropsychiatr Dis Treat</journal-id><journal-id journal-id-type="publisher-id">Neuropsychiatric Disease and Treatment</journal-id><journal-title-group><journal-title>Neuropsychiatric Disease and Treatment</journal-title></journal-title-group><issn pub-type="ppub">1176-6328</issn><issn pub-type="epub">1178-2021</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24855362</article-id><article-id pub-id-type="pmc">4019622</article-id><article-id pub-id-type="doi">10.2147/NDT.S60061</article-id><article-id pub-id-type="publisher-id">ndt-10-767</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Thorlund</surname><given-names>Kristian</given-names></name><xref ref-type="aff" rid="af1-ndt-10-767">1</xref><xref ref-type="aff" rid="af2-ndt-10-767">2</xref><xref ref-type="aff" rid="af4-ndt-10-767">4</xref><xref ref-type="corresp" rid="c1-ndt-10-767"></xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Ping</given-names></name><xref ref-type="aff" rid="af3-ndt-10-767">3</xref><xref ref-type="aff" rid="af4-ndt-10-767">4</xref></contrib><contrib contrib-type="author"><name><surname>Druyts</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="af3-ndt-10-767">3</xref><xref ref-type="aff" rid="af4-ndt-10-767">4</xref></contrib><contrib contrib-type="author"><name><surname>Eapen</surname><given-names>Shawn</given-names></name><xref ref-type="aff" rid="af3-ndt-10-767">3</xref><xref ref-type="aff" rid="af4-ndt-10-767">4</xref></contrib><contrib contrib-type="author"><name><surname>Mills</surname><given-names>Edward J</given-names></name><xref ref-type="aff" rid="af2-ndt-10-767">2</xref><xref ref-type="aff" rid="af3-ndt-10-767">3</xref><xref ref-type="aff" rid="af4-ndt-10-767">4</xref></contrib></contrib-group><aff id="af1-ndt-10-767"><label>1</label>Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada</aff><aff id="af2-ndt-10-767"><label>2</label>Stanford Prevention Research Center, Stanford University, Stanford, CA, USA</aff><aff id="af3-ndt-10-767"><label>3</label>Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada</aff><aff id="af4-ndt-10-767"><label>4</label>Redwood Outcomes, Vancouver, BC, Canada</aff><author-notes><corresp id="c1-ndt-10-767">Correspondence: Kristian Thorlund, Department of Clinical Epidemiology and Biostatistics, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada, Email <email>thorluk@mcmaster.ca</email></corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>07</day><month>5</month><year>2014</year></pub-date><volume>10</volume><fpage>767</fpage><lpage>776</lpage><permissions><copyright-statement>© 2014 Thorlund et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2014</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To compare the efficacy of the three nonergot dopamine-receptor agonists (DAs) pramipexole, ropinirole, and rotigotine for the treatment of early and advanced Parkinson’s disease (PD).</p></sec><sec><title>Materials and methods</title><p>Bayesian network meta-analyses were performed separately for early and advanced PD, and at time points 11–16 and 24–28 weeks. Outcomes for early PD included improvement on the Unified Parkinson’s Disease Rating Scale (UPDRS) activities in daily life (UPDRS-II), motor function (UPDRS-III), and their subtotal (UPDRS-II + III). Outcomes for advanced PD also included daily “off time” (hours), but not UPDRS-II + III.</p></sec><sec><title>Results</title><p>Totals of 23 and 24 trials informed early and advanced PD analyses. For early PD UPDRS-II at 11–16 weeks, pramipexole and rotigotine were statistically significantly superior to placebo, but ropinirole was not. For UPDRS-III and UPDRS-II + III, all DAs were statistically significantly better than placebo and exhibited similar improvements. At 24–28 weeks, results were also statistically significant for all DAs versus placebo, and the magnitudes of improvements were similar for pramipexole, ropinirole and rotigotine. Advanced PD improvements on UPDRS-II, UPRDS-III, and off time were statistically significant for pramipexole, ropinirole, and rotigotine versus placebo. At 11–16 weeks, rotigotine yielded slightly smaller effects than ropinirole and pramipexole, but credible intervals on differences were wide. For off time, results were near identical. At 24–28 weeks, results were similar for all three outcomes. Ropinirole yielded a slightly higher improvement on UPDRS-III, but a slightly smaller improvement in off time.</p></sec><sec><title>Conclusion</title><p>Our analyses suggest that pramipexole, ropinirole, and rotigotine exhibit similar efficacy in the treatment of early and advanced PD.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Parkinson’s disease</kwd><kwd>dopamine-receptor agonists</kwd><kwd>network meta-analysis</kwd></kwd-group></article-meta></front><floats-group><fig id="f1-ndt-10-767" position="float"><label>Figure 1</label><caption><p>Treatment networks for the three outcomes at the two time points for early Parkinson’s disease. The circles (nodes) represent each of the interventions where randomized clinical trial (RCT) data were available for the particular outcome. The lines between circles show which pair-wise comparisons were informed by RCTs, and the numbers on the lines show the number of RCTs informing a particular comparison.</p><p><bold>Abbreviations:</bold> UPDRS, Unified Parkinson’s Disease Rating Scale; DDCI, decarboxylase inhibitor.</p></caption><graphic xlink:href="ndt-10-767Fig1"></graphic></fig><fig id="f2-ndt-10-767" position="float"><label>Figure 2</label><caption><p>Treatment networks for the three outcomes at the two time points for advanced Parkinson’s disease. The circles (nodes) represent each of the interventions where randomized clinical trials (RCT) data was available for the particular outcome. The lines between circles show which pair wise comparisons were informed by RCTs, and the number in the lines show the number of RCTs informing a particular comparison.</p><p><bold>Abbreviation:</bold> UPDRS, Unified Parkinson’s Disease Rating Scale.</p></caption><graphic xlink:href="ndt-10-767Fig2"></graphic></fig><table-wrap id="t1-ndt-10-767" position="float"><label>Table 1</label><caption><p>Types of patients, interventions, controls, and outcomes (PICO) considered for the proposed study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">PICO</th><th colspan="2" align="left" valign="top" rowspan="1">Eligibility criteria and considered components
<hr></hr></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Early Parkinson’s patients</th><th align="left" valign="top" rowspan="1" colspan="1">Advanced Parkinson’s patients</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Population</td><td align="left" valign="top" rowspan="1" colspan="1">Adults over 18 years of age with early Parkinson’s disease</td><td align="left" valign="top" rowspan="1" colspan="1">Adults over 18 years of age with advanced Parkinson’s disease</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">Experimental interventions</td><td align="left" valign="top" rowspan="1" colspan="1">– Rotigotine</td><td align="left" valign="top" rowspan="1" colspan="1">– Rotigotine</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">– Ropinirole*</td><td align="left" valign="top" rowspan="1" colspan="1">– Ropinirole*</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">– Pramipexole*</td><td align="left" valign="top" rowspan="1" colspan="1">– Pramipexole*</td></tr><tr><td align="left" valign="top" rowspan="7" colspan="1">Control interventions</td><td align="left" valign="top" rowspan="1" colspan="1">– Placebo</td><td align="left" valign="top" rowspan="1" colspan="1">– Levodopa</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">– Levodopa</td><td align="left" valign="top" rowspan="1" colspan="1">– Levodopa + DDCI</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">– Levodopa + DDCI</td><td align="left" valign="top" rowspan="1" colspan="1">– Bromocriptine</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">– Bromocriptine</td><td align="left" valign="top" rowspan="1" colspan="1">– Cabergoline</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">– Cabergoline</td><td align="left" valign="top" rowspan="1" colspan="1">– Piribedil</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">– Piribedil</td><td align="left" valign="top" rowspan="1" colspan="1">– Pergolide</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">– Pergolide</td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">Outcomes</td><td align="left" valign="top" rowspan="1" colspan="1">– UPDRS-II (ADL)</td><td align="left" valign="top" rowspan="1" colspan="1">– UPDRS-II (ADL)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">– UPDRS-III (motor function)</td><td align="left" valign="top" rowspan="1" colspan="1">– UPDRS-III (motor function)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">– UPDRS-II + III</td><td align="left" valign="top" rowspan="1" colspan="1">– “Off time” reduction</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ndt-10-767"><p><bold>Notes:</bold> Levodopa was considered either alone or in combination with carbidopa or benserazide. *Immediate-release and extended-release formulations of both pramipexole and ropinirole were considered the same treatment.</p></fn><fn id="tfn2-ndt-10-767"><p><bold>Abbreviations:</bold> DDCI, decarboxylase inhibitor; UPDRS, Unified Parkinson’s Disease Rating Scale; ADL, activities in daily life.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ndt-10-767" position="float"><label>Table 2</label><caption><p>Analysis of early Parkinson’s disease population</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Comparison</th><th align="left" valign="top" rowspan="1" colspan="1">UPDRS-II</th><th align="left" valign="top" rowspan="1" colspan="1">UPDRS-III</th><th align="left" valign="top" rowspan="1" colspan="1">UPDRS-II + III</th></tr></thead><tbody><tr><td colspan="4" align="left" valign="top" rowspan="1">11–16 weeks</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> L-Dopa versus placebo</td><td align="left" valign="top" rowspan="1" colspan="1">−1.77 (−3.15 to −0.38)</td><td align="left" valign="top" rowspan="1" colspan="1">−6.09 (−8.29 to −3.89)</td><td align="left" valign="top" rowspan="1" colspan="1">−8.59 (−10.8 to −6.26)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Pramipexole versus placebo</td><td align="left" valign="top" rowspan="1" colspan="1">−1.15 (−1.77 to −0.38)</td><td align="left" valign="top" rowspan="1" colspan="1">−3.40 (−4.56 to −2.44)</td><td align="left" valign="top" rowspan="1" colspan="1">−4.33 (−5.35 to −3.32)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Ropinirole versus placebo</td><td align="left" valign="top" rowspan="1" colspan="1">−1.28 (−3.44 to 0.87)</td><td align="left" valign="top" rowspan="1" colspan="1">−2.85 (−5.09 to −0.89)</td><td align="left" valign="top" rowspan="1" colspan="1">−4.18 (−6.15 to −2.26)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rotigotine versus placebo</td><td align="left" valign="top" rowspan="1" colspan="1">−1.01 (−1.68 to −0.33)</td><td align="left" valign="top" rowspan="1" colspan="1">−3.34 (−4.99 to −1.71)</td><td align="left" valign="top" rowspan="1" colspan="1">−4.52 (−5.70 to −3.29)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Pramipexole versus L-Dopa</td><td align="left" valign="top" rowspan="1" colspan="1">0.62 (−0.60 to 1.88)</td><td align="left" valign="top" rowspan="1" colspan="1">2.71 (0.63 to 4.64)</td><td align="left" valign="top" rowspan="1" colspan="1">4.26 (1.06 to 6.35)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Ropinirole versus L-Dopa</td><td align="left" valign="top" rowspan="1" colspan="1">0.56 (−1.54 to 2.54)</td><td align="left" valign="top" rowspan="1" colspan="1">3.25 (0.92 to 5.39)</td><td align="left" valign="top" rowspan="1" colspan="1">4.42 (1.78 to 6.90)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rotigotine versus L-Dopa</td><td align="left" valign="top" rowspan="1" colspan="1">0.76 (−0.57 to 2.16)</td><td align="left" valign="top" rowspan="1" colspan="1">2.76 (0.18 to 5.33)</td><td align="left" valign="top" rowspan="1" colspan="1">4.08 (1.56 to 6.58)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Ropinirole versus pramipexole</td><td align="left" valign="top" rowspan="1" colspan="1">−0.11 (−2.24 to 2.25)</td><td align="left" valign="top" rowspan="1" colspan="1">0.57 (−1.70 to 2.76)</td><td align="left" valign="top" rowspan="1" colspan="1">0.15 (−1.94 to 2.22)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rotigotine versus pramipexole</td><td align="left" valign="top" rowspan="1" colspan="1">0.14 (−0.97 to 0.70)</td><td align="left" valign="top" rowspan="1" colspan="1">0.06 (−2.77 to 2.10)</td><td align="left" valign="top" rowspan="1" colspan="1">−0.17 (−1.61 to 1.40)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rotigotine versus ropinirole</td><td align="left" valign="top" rowspan="1" colspan="1">0.28 (−2.41 to 1.98)</td><td align="left" valign="top" rowspan="1" colspan="1">−0.50 (−3.01 to 2.30)</td><td align="left" valign="top" rowspan="1" colspan="1">0.32 (−2.00 to 2.58)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">24–28 weeks</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> L-Dopa versus placebo</td><td align="left" valign="top" rowspan="1" colspan="1">−2.76 (−4.77 to −0.81)</td><td align="left" valign="top" rowspan="1" colspan="1">−7.26 (−10.7 to −3.86)</td><td align="left" valign="top" rowspan="1" colspan="1">−9.15 (−13.2 to −4.83)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Pramipexole versus placebo</td><td align="left" valign="top" rowspan="1" colspan="1">−1.67 (−2.64 to −0.72)</td><td align="left" valign="top" rowspan="1" colspan="1">−4.37 (−6.16 to −2.63)</td><td align="left" valign="top" rowspan="1" colspan="1">−6.05 (−8.84 to −3.19)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Ropinirole versus placebo</td><td align="left" valign="top" rowspan="1" colspan="1">−2.39 (−4.71 to 0.12)</td><td align="left" valign="top" rowspan="1" colspan="1">−5.08 (−7.28 to −2.85)</td><td align="left" valign="top" rowspan="1" colspan="1">−6.32 (−10.4 to −2.00)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rotigotine versus placebo</td><td align="left" valign="top" rowspan="1" colspan="1">−1.70 (−2.91 to −0.45)</td><td align="left" valign="top" rowspan="1" colspan="1">−3.78 (−6.20 to −1.23)</td><td align="left" valign="top" rowspan="1" colspan="1">−5.35 (−9.33 to −1.43)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Pramipexole versus L-Dopa</td><td align="left" valign="top" rowspan="1" colspan="1">1.09 (−0.63 to 2.83)</td><td align="left" valign="top" rowspan="1" colspan="1">2.86 (0.24 to 5.51)</td><td align="left" valign="top" rowspan="1" colspan="1">3.09 (−1.18 to 7.17)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Ropinirole versus L-Dopa</td><td align="left" valign="top" rowspan="1" colspan="1">0.38 (−0.97 to 1.94)</td><td align="left" valign="top" rowspan="1" colspan="1">2.15 (0.06 to 4.38)</td><td align="left" valign="top" rowspan="1" colspan="1">2.82 (−0.80 to 6.48)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rotigotine versus L-Dopa</td><td align="left" valign="top" rowspan="1" colspan="1">1.06 (−1.23 to 3.43)</td><td align="left" valign="top" rowspan="1" colspan="1">3.46 (−0.03 to 7.17)</td><td align="left" valign="top" rowspan="1" colspan="1">3.78 (−2.00 to 9.40)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Ropinirole versus pramipexole</td><td align="left" valign="top" rowspan="1" colspan="1">−0.72 (−2.82 to 1.64)</td><td align="left" valign="top" rowspan="1" colspan="1">−0.71 (−3.15 to 1.84)</td><td align="left" valign="top" rowspan="1" colspan="1">−0.25 (−4.67 to 4.34)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rotigotine versus pramipexole</td><td align="left" valign="top" rowspan="1" colspan="1">−0.03 (−1.55 to 1.54)</td><td align="left" valign="top" rowspan="1" colspan="1">0.61 (−2.32 to 3.69)</td><td align="left" valign="top" rowspan="1" colspan="1">0.70 (−4.07 to 5.46)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rotigotine versus ropinirole</td><td align="left" valign="top" rowspan="1" colspan="1">0.69 (−2.11 to 3.31)</td><td align="left" valign="top" rowspan="1" colspan="1">1.34 (−1.94 to 4.62)</td><td align="left" valign="top" rowspan="1" colspan="1">0.97 (−4.82 to 6.58)</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-ndt-10-767"><p><bold>Notes:</bold> Mean differences and 95% credible intervals between active interventions and placebo for change from baseline on UPDRS-II, UPDRS-III, and UPDRS-II + III subtotal at 11–16 weeks and at 24–28 weeks after titration. Negative mean difference indicates superiority of the active intervention.</p></fn><fn id="tfn4-ndt-10-767"><p><bold>Abbreviation:</bold> UPDRS, Unified Parkinson’s Disease Rating Scale.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ndt-10-767" position="float"><label>Table 3</label><caption><p>Analysis of advanced Parkinson’s disease population</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Comparison</th><th align="left" valign="top" rowspan="1" colspan="1">UPDRS−II</th><th align="left" valign="top" rowspan="1" colspan="1">UPDRS−III</th><th align="left" valign="top" rowspan="1" colspan="1">Off time</th></tr></thead><tbody><tr><td colspan="4" align="left" valign="top" rowspan="1">11–16 weeks</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Pramipexole versus placebo</td><td align="left" valign="top" rowspan="1" colspan="1">−2.03 (−2.69 to −1.37)</td><td align="left" valign="top" rowspan="1" colspan="1">−5.03 (−6.73 to −3.39)</td><td align="left" valign="top" rowspan="1" colspan="1">−1.53 (−2.11 to −0.95)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Ropinirole versus placebo</td><td align="left" valign="top" rowspan="1" colspan="1">−1.84 (−3.22 to −0.44)</td><td align="left" valign="top" rowspan="1" colspan="1">−5.01 (−8.43 to −1.63)</td><td align="left" valign="top" rowspan="1" colspan="1">−1.44 (−2.06 to −0.79)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rotigotine versus placebo</td><td align="left" valign="top" rowspan="1" colspan="1">−1.71 (−2.62 to −0.78)</td><td align="left" valign="top" rowspan="1" colspan="1">−3.84 (−6.94 to −0.89)</td><td align="left" valign="top" rowspan="1" colspan="1">−1.52 (−2.46 to −0.47)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Ropinirole versus pramipexole</td><td align="left" valign="top" rowspan="1" colspan="1">0.18 (−1.27 to 1.62)</td><td align="left" valign="top" rowspan="1" colspan="1">0.00 (−3.73 to 3.83)</td><td align="left" valign="top" rowspan="1" colspan="1">−0.11 (−0.74 to 0.91)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rotigotine versus pramipexole</td><td align="left" valign="top" rowspan="1" colspan="1">0.32 (−0.68 to 1.35)</td><td align="left" valign="top" rowspan="1" colspan="1">1.21 (−1.77 to 4.11)</td><td align="left" valign="top" rowspan="1" colspan="1">−0.01 (−0.99 to 1.06)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rotigotine versus ropinirole</td><td align="left" valign="top" rowspan="1" colspan="1">0.13 (−1.51 to 1.74)</td><td align="left" valign="top" rowspan="1" colspan="1">1.20 (−3.49 to 5.65)</td><td align="left" valign="top" rowspan="1" colspan="1">0.06 (−1.13 to 1.19)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">24–28 weeks</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Pramipexole versus placebo</td><td align="left" valign="top" rowspan="1" colspan="1">−2.18 (−2.96 to −1.42)</td><td align="left" valign="top" rowspan="1" colspan="1">−4.22 (−6.31 to −2.37)</td><td align="left" valign="top" rowspan="1" colspan="1">−1.60 (−3.27 to −0.59)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Ropinirole versus placebo</td><td align="left" valign="top" rowspan="1" colspan="1">−2.20 (−3.24 to −1.14)</td><td align="left" valign="top" rowspan="1" colspan="1">−4.84 (−7.33 to −2.55)</td><td align="left" valign="top" rowspan="1" colspan="1">−1.17 (−2.49 to −0.31)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rotigotine versus placebo</td><td align="left" valign="top" rowspan="1" colspan="1">−2.25 (−3.71 to −0.78)</td><td align="left" valign="top" rowspan="1" colspan="1">−4.28 (−7.63 to −1.12)</td><td align="left" valign="top" rowspan="1" colspan="1">−1.49 (−2.91 to −0.05)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Ropinirole versus pramipexole</td><td align="left" valign="top" rowspan="1" colspan="1">0.02 (−1.29 to 1.31)</td><td align="left" valign="top" rowspan="1" colspan="1">0.74 (−3.58 to 2.28)</td><td align="left" valign="top" rowspan="1" colspan="1">0.45 (−0.89 to 1.59)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rotigotine versus pramipexole</td><td align="left" valign="top" rowspan="1" colspan="1">0.06 (−1.62 to 1.77)</td><td align="left" valign="top" rowspan="1" colspan="1">−0.07 (−3.87 to 3.73)</td><td align="left" valign="top" rowspan="1" colspan="1">0.10 (−1.68 to 1.79)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Rotigotine versus ropinirole</td><td align="left" valign="top" rowspan="1" colspan="1">0.05 (−1.71 to 1.91)</td><td align="left" valign="top" rowspan="1" colspan="1">0.64 (−3.41 to 4.60)</td><td align="left" valign="top" rowspan="1" colspan="1">−0.33 (−1.98 to 1.42)</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-ndt-10-767"><p><bold>Notes:</bold> Mean differences and 95% credible intervals between active interventions and placebo for change from baseline on UPDRS-II, UPDRS-III, and “off time” at 11–16 weeks and 24–28 weeks after titration. Negative mean difference indicates superiority of the first intervention.</p></fn><fn id="tfn6-ndt-10-767"><p><bold>Abbreviation:</bold> UPDRS, Unified Parkinson’s Disease Rating Scale.</p></fn></table-wrap-foot></table-wrap></floats-group></pmc><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Ontario</li></region><settlement><li>Hamilton (Ontario)</li></settlement><orgName><li>Université McMaster</li></orgName></list><tree><country name="Canada"><region name="Ontario"><name sortKey="Thorlund, Kristian" sort="Thorlund, Kristian" uniqKey="Thorlund K" first="Kristian" last="Thorlund">Kristian Thorlund</name></region><name sortKey="Druyts, Eric" sort="Druyts, Eric" uniqKey="Druyts E" first="Eric" last="Druyts">Eric Druyts</name><name sortKey="Druyts, Eric" sort="Druyts, Eric" uniqKey="Druyts E" first="Eric" last="Druyts">Eric Druyts</name><name sortKey="Eapen, Shawn" sort="Eapen, Shawn" uniqKey="Eapen S" first="Shawn" last="Eapen">Shawn Eapen</name><name sortKey="Eapen, Shawn" sort="Eapen, Shawn" uniqKey="Eapen S" first="Shawn" last="Eapen">Shawn Eapen</name><name sortKey="Mills, Edward J" sort="Mills, Edward J" uniqKey="Mills E" first="Edward J" last="Mills">Edward J. Mills</name><name sortKey="Mills, Edward J" sort="Mills, Edward J" uniqKey="Mills E" first="Edward J" last="Mills">Edward J. Mills</name><name sortKey="Thorlund, Kristian" sort="Thorlund, Kristian" uniqKey="Thorlund K" first="Kristian" last="Thorlund">Kristian Thorlund</name><name sortKey="Wu, Ping" sort="Wu, Ping" uniqKey="Wu P" first="Ping" last="Wu">Ping Wu</name><name sortKey="Wu, Ping" sort="Wu, Ping" uniqKey="Wu P" first="Ping" last="Wu">Ping Wu</name></country><country name="États-Unis"><noRegion><name sortKey="Thorlund, Kristian" sort="Thorlund, Kristian" uniqKey="Thorlund K" first="Kristian" last="Thorlund">Kristian Thorlund</name></noRegion><name sortKey="Mills, Edward J" sort="Mills, Edward J" uniqKey="Mills E" first="Edward J" last="Mills">Edward J. Mills</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001768 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001768 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:4019622
|texte= Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:24855362" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |